Foghorn Therapeutics (FHTX) Other Non Operating Income (2019 - 2026)
Foghorn Therapeutics' (FHTX) quarterly Other Non Operating Income came in at -$44000.0 in Q1 2026, down 103.17% year-on-year from $1.4 million in Q1 2025, and down 108.76% quarter-over-quarter from $502000.0 in Q4 2025.
Foghorn Therapeutics (FHTX) Other Non Operating Income (2019 - 2026) Analysis & Trends
Foghorn Therapeutics' Other Non Operating Income history runs 8 years deep, the most recent figure standing at -$44000.0 for Q1 2026.
- On a quarterly basis, Other Non Operating Income fell 103.17% year-over-year to -$44000.0 in Q1 2026; TTM through Mar 2026 was $1.9 million, a 59.88% decrease from a year earlier, with the FY2025 full-year figure at $3.4 million, down 19.26% from the prior year.
- Other Non Operating Income slipped to -$44000.0 in Q1 2026 per FHTX's latest filing, from $502000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.4 million in Q4 2024 and bottomed at -$44000.0 in Q1 2026.
- The 5-year median for Other Non Operating Income is $712000.0 (2023), against an average of $758294.1.
- Across the five-year window, Other Non Operating Income surged 152.0% in 2022 and slumped 103.17% in 2026, its largest moves.
- Year by year, Other Non Operating Income stood at $624000.0 in 2022, then advanced by 8.65% to $678000.0 in 2023, then surged by 107.37% to $1.4 million in 2024, then plunged by 64.3% to $502000.0 in 2025, then plunged by 108.76% to -$44000.0 in 2026.
- Per Business Quant, the three latest FHTX Other Non Operating Income figures stand at -$44000.0 (Q1 2026), $502000.0 (Q4 2025), and $620000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44,000.00 |
| Dec 31, 2025 | 502,000.00 |
| Sep 30, 2025 | 620,000.00 |
| Jun 30, 2025 | 852,000.00 |
| Mar 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | 1.41 Mn |
| Sep 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 783,000.00 |
| Mar 31, 2024 | 739,000.00 |
| Dec 31, 2023 | 678,000.00 |
| Sep 30, 2023 | 721,000.00 |
| Jun 30, 2023 | 712,000.00 |
| Mar 31, 2023 | 720,000.00 |
| Dec 31, 2022 | 624,000.00 |
| Sep 30, 2022 | 651,000.00 |
| Jun 30, 2022 | 650,000.00 |
| Mar 31, 2022 | 655,000.00 |
| Dec 31, 2021 | -1.20 Mn |
| Sep 30, 2021 | 680,000.00 |
| Jun 30, 2021 | 645,000.00 |